The Island Where You Can Buy FDA-Illegal Gene Therapy for $25,000 and Call It Real Estate

How Prospera ZEDE on Roatan, Honduras became the only place on earth where a $25,000 gene therapy injection and a Bitcoin-priced condo are the same real estate pitch.

Landlord Ledger Publications • Profile • 2026-06-14

On a 58-acre enclave carved out of the Caribbean island of Roatan, Honduras, the most unusual real estate market on earth is quietly expanding. Prospera ZEDE is a privately governed charter city incorporated in 2017 and backed by Peter Thiel, Marc Andreessen, and Sam Altman. It operates under U.S. common law administered by a Delaware corporation, accepts Bitcoin as its sole legal tender, levies a 1% business revenue tax instead of income taxes, and hosts more than 300 registered companies. But what makes real estate in Prospera genuinely unlike any other property market in the world is not the Bitcoin pricing or the Zaha Hadid-designed residences currently under development. It is what the property rights enable: access to gene therapy that is not approved by the FDA and could not be legally administered in the United States, sold at $25,000 per injection, administered in a clinical setting on the grounds of a charter city that argues it is not subject to Honduran national law, let alone American regulation.

The Governance Architecture

Prospera was incorporated by CEO Erick Brimen, a Venezuelan-born wealth fund manager who previously ran NeWay Capital. It sits within the legal framework of Honduras's Zones for Employment and Economic Development (ZEDEs), semi-autonomous regions that under Honduran constitutional amendments passed in 2013 were granted the authority to create their own legal systems, courts, and tax regimes. ZEDEs remain nominally part of Honduras but are subject to Honduran law only on matters of sovereignty, defense, and foreign affairs. Everything else: contracts, property rights, regulatory oversight, medical standards. These fall within the ZEDE's own jurisdiction.

The governance structure made Prospera a magnet for libertarian capital. Thiel and Naval Ravikant, co-founder of AngelList, invested at least $150,000 in Minicircle, the gene therapy startup that would later set up its first clinical site in Prospera. Sam Altman confirmed to MIT Technology Review that he invested $250,000 in the same company. Andreessen Horowitz and related Silicon Valley networks have backed Prospera's core infrastructure. In 2022, Prospera announced Bitcoin as legal tender within its borders, allowing residents and businesses to pay taxes, settle contracts, and transact entirely in cryptocurrency with no capital gains liability. By late 2025, total investment raised across the jurisdiction had reached approximately $200 million, and the zone represented roughly a third of all greenfield FDI into Honduras in 2022 alone.

The legal situation is now complicated. In September 2024, the Honduran Supreme Court declared the entire ZEDE framework unconstitutional with retroactive effect, treating the legal basis for Prospera's existence as void since 2013. Prospera's response has been to sue the government of Honduras for $10.7 billion, equivalent to roughly one-third of the country's GDP, through a CAFTA-DR arbitration at ICSID, arguing that the retroactive ruling constitutes unlawful expropriation of vested investor rights. As of mid-2026, Prospera remains operational. Construction continues. The arbitration is pending.

The Biotech Corridor

Inside this contested jurisdiction, two biotech companies have established what amounts to a regulatory-exempt clinical corridor for human gene therapy trials on healthy people.

Minicircle, incorporated in Delaware and headquartered in Austin, set up a clinical site in Prospera in 2021. The company's core product is a follistatin gene therapy: an injection of circular DNA molecules that instruct the body to massively increase its production of follistatin, a protein implicated in muscle growth, bone density, and inflammation suppression. The effects are said to last one to two years. The therapy is not approved by the FDA. In Prospera, it is sold at the GARM Clinic on Roatan for $25,000 per injection, with a second site at the Eterna Health Clinic in Dubai.

Minicircle conducted a 44-person trial in which participants aged 23 to 89 received identical doses and were tracked for three months. The company claims participants shaved approximately 11 years from their genetic age. No peer-reviewed clinical trial data has been published to support this claim.

Bryan Johnson, the longevity-obsessed tech entrepreneur who spends roughly $2 million annually on his Blueprint anti-aging protocol, flew to Roatan and received the injection. Minicircle did not charge him. The procedure was documented in the Netflix documentary "Don't Die: The Man Who Wants to Live Forever," released in January 2025, which brought Prospera's gene therapy market to a global audience. Six months after the injection, the documentary reports, Johnson's muscle mass had increased by 7%. He also reported a 160% spike in circulating follistatin levels. Walter Patterson, Minicircle's co-founder and chief scientific officer, told Bloomberg that the $25,000 price point represents a bargain by gene therapy standards: "Most gene therapies cost more than $1 million a pop."

The second company, Unlimited Bio, was incorporated in Prospera the following year. Its CEO, Ivan Morgunov, is a Russian-Israeli computer scientist who has said publicly that he could be among "the last generation throughout human history to die from old age." His chief operating officer, Vladimir Leshko, a former electrical engineer and professional poker player who retrained in biomedical engineering, has been direct about the company's geographic logic: "A company like ours couldn't exist outside of Prospera."

Unlimited Bio is running trials on a two-therapy combination: a follistatin gene therapy and a vascular endothelial growth factor (VEGF) therapy designed to stimulate blood vessel growth. Of the 12 to 15 volunteers enrolled, half receive follistatin alone; the other half receive both therapies simultaneously. Volunteers cover their own travel and treatment costs. The company received a $40 million strategic investment from Immortal Dragons, a longevity fund, in October 2025. Its VEGF therapy is already accessible at clinics in Honduras and Mexico, and the profile of patients willing to travel for it has expanded: Khloe Kardashian tagged Unlimited Bio in a social media post about stem-cell treatments she and her sister Kim received at the Eterna clinic in August 2025.

What the Science Says

Scientists not affiliated with either company have raised serious concerns about both the methods and the claims.

Holly Fernandez Lynch, a lawyer and medical ethicist at the University of Pennsylvania, has stated that drawing meaningful conclusions from trials of 12 to 15 people is impossible, and that such a study cannot demonstrate anything about longevity in any statistically meaningful way.

Seppo Yla-Herttuala, a professor of molecular medicine at the University of Eastern Finland who has studied VEGF for decades, has noted that the safety of VEGF therapy depends critically on dosage and injection site. Prior attempts to deliver VEGF therapy to the heart have resulted in edema, a sometimes fatal buildup of fluid. If VEGF travels to the eye, it can cause blindness. He expressed skepticism about assurances that the compound would remain localized. Christin Glorioso, a physician and neuroscientist, wrote in a longevity newsletter that unregulated follistatin therapies "have no evidence for working, don't make sense from a scientific perspective and likely will kill someone by inducing cancer or liver failure."

Leigh Turner, executive director of the bioethics program at the University of California Irvine, has described the broader concern with jurisdictions like Prospera: "There can be clinics and hospitals that no one's really paying much attention to, in terms of what kinds of marketing claims they're making, or what clinical practices they're engaged in." Minicircle's CEO Mac Davis, known informally as "Mac," short for Machiavelli, has framed his project in explicitly anti-regulatory terms, describing the goal as trying things out and not being "hampered by fear and regulation."

The Real Estate Play

The biotech corridor is driving a distinct luxury real estate proposition, one that fuses charter-city governance with medical tourism infrastructure.

In 2024, Duna Residences opened as the first large-scale newbuild in Prospera. The 14-story mixed-use development includes 82 residences available for purchase or lease, alongside commercial and retail space. More prominent is Beyabu, a residential project designed by Zaha Hadid Architects. The design uses modular timber construction, with curved palapa roofs and rounded balconies derived from local building traditions. Timber will be sourced from certified forests on mainland Honduras and treated locally, part of a stated commitment to a regional supply chain. Pristine Heights, a high-end development at the resort side of the community, has also been announced. A fourth project, Darien Village, was announced in 2025.

Property transactions in Prospera can be denominated in Bitcoin, down to the satoshi, and the tax burden on owners is capped at 1% of business revenue plus a 5% ZEDE contribution, with no income or capital gains taxes. The combination of architectural ambition, regulatory permissiveness, and direct adjacency to the gene therapy clinics positions Prospera's housing market as something closer to a longevity campus than a residential development. Prospera projects 38,000 residents by 2030 and over $500 million in total FDI.

The Arbitration Overhang

The real estate market's deepest risk is not the therapy's efficacy but the jurisdiction's survival.

The Honduran Supreme Court's September 2024 ruling declared the ZEDE framework unconstitutional from its inception, meaning Prospera's contracts, permits, and legal protections may have no domestic legal standing. Prospera's legal team has countered that its 50-year stability guarantee under international investment treaties supersedes domestic constitutional rulings, and that retroactive invalidation constitutes expropriation under CAFTA-DR. The ICSID tribunal has declined to dismiss the claims on preliminary grounds, meaning the arbitration will proceed. Honduras withdrew from ICSID entirely in August 2024 to prevent future arbitration claims, though pending cases remain active.

For property buyers, the implication is stark: a purchase in Prospera is a bet on international arbitration law rather than Honduran property law. The governing legal system is not the state in which the land sits but the tribunal proceedings underway at the World Bank. What gets built inside this zone, condos priced in satoshis, timber houses by the firm that designed the Heydar Aliyev Centre, clinics offering gene therapy at one-fortieth the price of a conventional FDA-approved treatment, all rests on the outcome of a $10.7 billion lawsuit against a country whose entire GDP runs to roughly $32 billion.

The GARM Clinic on Roatan is still administering injections. Zaha Hadid Architects' residences are still scheduled to break ground. And somewhere in the arbitration queue at ICSID, the legal question of whether any of it was ever real property under any recognized law remains unresolved.